Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There was no significant difference between the groups in terms of nutrient intakes (Table 3).Comparison of anthropometric and questionnaire scores between PSST groupsVariableTotal N = 139Mild n = 57Moderate n = 45Severe n = 41pMeanSDMeanSDMeanSDMeanSDWeight (kg)70.439.1270.7110.4470.048.5670.497.800.934Height (cm)158.625.32157.915.50158.294.83160.035.500.149BMI (kg/m2)22.202.8622.493.3822.092.6621.882.220.588Waist circumference (cm)89.607.0090.447.9589.976.6887.955.670.222Hip circumference (cm)105.637.41105.679.00106.217.01104.895.030.724Waist-to-hip ratio0.850.050.860.060.850.050.840.040.205Wrist circumference (cm)15.861.2915.791.2115.961.3715.851.330.819Neck (cm)34.252.6333.972.7934.542.4534.312.630.556Mid-arm-circumference (cm)30.893.0530.813.5331.262.8330.592.560.596Quality of life score91.0911.1891.879.5289.7112.8491.5811.440.602QUIKI0.320.020.320.020.330.020.320.030.413Serum vitamin D (ng/mL)14.975.1614.765.5315.164.6115.055.340.922†VariableTotal N = 139Mild n = 57Moderate n = 45Severe n = 41pFrequency%Frequency%Frequency%Frequency%Vitamin D status 1st tertile11482.04785.53884.42974.40.472‡ 2nd tertile2316.5712.7613.31025.6 3rd tertile21.411.812.200.0Metabolic syndrome5941.32850.91328.91846.20.110ǂCKD stage 3b14099.355100.04497.841100.00.639‡ Other10.700.012.200.0One-way analysis of variance (ANOVA) and Tukey post hoc test were used for the comparison‡The Monte Carlo test was used for the comparisonǂThe chi square test was used for the comparisonComparison of nutrient intakes between PSST groupsVariableTotal N = 139Mild n = 57Moderate n = 45Severe n = 41pMeanSDMeanSDMeanSDMeanSDProtein (g)69.2533.3770.0829.1570.5144.9066.4621.600.863Fat (g)82.3032.2485.3234.3379.5134.0481.1426.880.696SFA (g)31.0613.9032.5713.0930.2715.7629.7812.860.632MUFA (g)30.0115.5330.4817.2328.0813.0631.6715.840.615PUFA (g)13.106.0913.757.4812.544.5713.145.390.533Trans fatty acid (g)2.391.712.611.752.401.872.051.390.368Cholesterol (mg)328.03153.290320.46139.33345.25179.28318.42141.790.703Carbohydrate (g)221.17115.23216.3473.37221.62170.26231.6982.150.849Energy (kcal)1881.99730.971898.42643.961853.11958.651892.46526.580.957Fiber (g)20.9317.7521.149.9021.7528.4619.607.510.879Sodium (g)1543.011093.881496.54629.011689.691720.761433.64534.140.587Potassium (g)2879.371194.382961.551047.242774.981403.962882.731153.850.777Calcium (mg)738.72416.16736.13353.57774.49547.22697.73315.510.751Magnesium (mg)304.01189.93308.13129.18304.32283.18297.37110.770.971Phosphorus (mg)1200.61622.031201.75439.861244.22911.741145.43394.630.809Iron (mg)10.907.1610.584.5311.6910.8910.414.180.707Copper (mg)2.731.642.521.172.962.112.761.660.461Zinc (mg)8.444.828.373.308.777.248.162.750.866Chloride (mg)2626.711770.012563.771027.752835.732785.032465.91857.610.659Manganese (mg)5.564.465.362.636.057.145.281.550.714Selenium (µg)63.3235.1758.7425.0268.9345.4763.3934.060.418Iodine (µg)97.5163.74102.7575.3392.7052.3695.4758.430.757Retinol (µg)434.69230.55407.37203.02472.44270.58429.83217.4050.433Carotene (µg)1219.17908.981192.99754.311129.35863.271368.981158.120.539Vitamin D (µg)1.390.711.420.781.400.761.350.570.920Vitamin E (mg)11.477.3511.198.8810.976.1112.496.210.662Thiamin (mg)1.460.781.480.571.451.111.430.550.964Riboflavin (mg)2.341.212.220.942.541.392.271.340.461Niacin (mg)16.8511.3016.557.7417.7516.9916.196.370.830Vitamin B6 (mg)6.695.045.923.247.656.316.695.490.293Vitamin B12 (µg)17.4713.3615.418.8620.2616.5117.2014.530.250Folate (µg)274.72134.01273.2897.89281.92189.43268.0998.910.910Panthotenate (mg)6.983.236.832.597.214.126.923.230.861Biotin (µg)58.8129.4057.6225.7159.9535.7159.2826.860.933Vitamin C (mg)214.59146.54232.35171.13185.1397.27223.77155.100.312One-way analysis of variance (ANOVA) and Tukey post hoc test were used for the comparison
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Factors associated with the severity of premenstrual symptoms in women with central obesity: a cross-sectional study
Source: Article title.
Data of 143 women were selected from the 346 adults who were screened for eligibility to participate in the SUVINA study.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Factors associated with the severity of premenstrual symptoms in women with central obesity: a cross-sectional study
Cross-sectional study · Journal of Health, Population, and Nutrition · 2023
Original publication title
Factors associated with the severity of premenstrual symptoms in women with central obesity: a cross-sectional study
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Premenstrual syndrome (PMS) is a common condition that affects social and psychological well-being of women. The risk of PMS is higher among obese women. The aim of this study was to identify the factors that influence the severity of PMS in women with central obesity.
Source: IntroductionAbstract: What methods does the paper describe?
This cross-sectional study was performed on 30 to 50 year-old women with abdominal obesity (waist circumference > 80 cm). The following data were collected: demographic data, anthropometric measurements, premenstrual symptoms screening tools, semi-quantitative food frequency questionnaire, 42-item depression, anxiety, and stress questionnaire (DASS-42), as well as serum vitamin D, and renal function tests.
Source: Materials and methodsAbstract: Results
A total of 139 women (mean age of 41.40 ± 7.39 years old) participated in the study. The prevalence of mild, moderate and severe premenstrual symptoms was 38.7% (55/142), 31.7% (45/142) and 27.5% (39/142), respectively. There was no significant difference between the groups in terms of anthropometric measurements and energy-adjusted nutrient intakes (p > 0.05). There was a significant relationship between moderate PMS and energy-adjusted saturated fatty acid (SFA) (p = .018, OR = .010 and 95% CI for OR: < .001 and .452), and energy-adjusted riboflavin (p = .042, OR = .005, 95% CI for OR: < .001 and .821), and between severe PMS and age (p = .034, OR = .906, 95% CI for OR: .826 and .993), and energy-adjusted monounsaturated fatty acid (MUFA) intake (p = .041, OR = 23.789, 95% CI for OR: 1.138 and 497.294).
Source: ResultsAbstract: Conclusion
High intakes of MUFA and younger age were associated with a greater severity of PMS, while riboflavin intake was associated with reduced PMS severity.
Source: ConclusionAuthors’ abstract
Introduction
Premenstrual syndrome (PMS) is a common condition that affects social and psychological well-being of women. The risk of PMS is higher among obese women. The aim of this study was to identify the factors that influence the severity of PMS in women with central obesity.
Materials and methods
This cross-sectional study was performed on 30 to 50 year-old women with abdominal obesity (waist circumference > 80 cm). The following data were collected: demographic data, anthropometric measurements, premenstrual symptoms screening tools, semi-quantitative food frequency questionnaire, 42-item depression, anxiety, and stress questionnaire (DASS-42), as well as serum vitamin D, and renal function tests.
Results
A total of 139 women (mean age of 41.40 ± 7.39 years old) participated in the study. The prevalence of mild, moderate and severe premenstrual symptoms was 38.7% (55/142), 31.7% (45/142) and 27.5% (39/142), respectively. There was no significant difference between the groups in terms of anthropometric measurements and energy-adjusted nutrient intakes (p > 0.05). There was a significant relationship between moderate PMS and energy-adjusted saturated fatty acid (SFA) (p = .018, OR = .010 and 95% CI for OR: < .001 and .452), and energy-adjusted riboflavin (p = .042, OR = .005, 95% CI for OR: < .001 and .821), and between severe PMS and age (p = .034, OR = .906, 95% CI for OR: .826 and .993), and energy-adjusted monounsaturated fatty acid (MUFA) intake (p = .041, OR = 23.789, 95% CI for OR: 1.138 and 497.294).
Conclusion
High intakes of MUFA and younger age were associated with a greater severity of PMS, while riboflavin intake was associated with reduced PMS severity.
Publication and source details
Original title: Factors associated with the severity of premenstrual symptoms in women with central obesity: a cross-sectional study
Payam Sharifan; Ali Jafarzadeh Esfehani; Amir Zamiri; Mansoureh Sadat Ekhteraee Toosi; Fatemeh Najar Sedgh Doust; Niloufar Taghizadeh; Maryam Mohammadi-Bajgiran; Hamideh Ghazizadeh; Fatemeh Khorram Rouz; Gordon Ferns; Majid Ghayour-Mobarhan
Journal of Health, Population, and Nutrition · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T07:50:34.414481+00:00
DOI: 10.1186/s41043-022-00343-5 · PMC9926716